ES3054693T3 - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents
Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorderInfo
- Publication number
- ES3054693T3 ES3054693T3 ES17881161T ES17881161T ES3054693T3 ES 3054693 T3 ES3054693 T3 ES 3054693T3 ES 17881161 T ES17881161 T ES 17881161T ES 17881161 T ES17881161 T ES 17881161T ES 3054693 T3 ES3054693 T3 ES 3054693T3
- Authority
- ES
- Spain
- Prior art keywords
- bipolar disorder
- mania
- pharmaceutical composition
- compound
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170224 | 2016-12-14 | ||
| PCT/KR2017/014740 WO2018111008A1 (ko) | 2016-12-14 | 2017-12-14 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3054693T3 true ES3054693T3 (en) | 2026-02-05 |
Family
ID=62559442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17881161T Active ES3054693T3 (en) | 2016-12-14 | 2017-12-14 | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11571410B2 (enExample) |
| EP (1) | EP3556366B1 (enExample) |
| JP (1) | JP7208139B2 (enExample) |
| KR (1) | KR102635938B1 (enExample) |
| CN (1) | CN110290788A (enExample) |
| AU (1) | AU2017374458B2 (enExample) |
| BR (1) | BR112019011930A2 (enExample) |
| CL (1) | CL2019001618A1 (enExample) |
| ES (1) | ES3054693T3 (enExample) |
| IL (1) | IL267195B2 (enExample) |
| MX (1) | MX2019006940A (enExample) |
| MY (1) | MY199104A (enExample) |
| WO (1) | WO2018111008A1 (enExample) |
| ZA (1) | ZA201903747B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281559B2 (en) * | 2018-09-21 | 2025-06-01 | Sk Biopharmaceuticals Co Ltd | (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| CN113242735A (zh) * | 2018-09-21 | 2021-08-10 | 爱思开生物制药株式会社 | 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作 |
| AU2020389425B2 (en) * | 2019-11-22 | 2026-03-05 | Sk Biopharmaceuticals Co., Ltd. | Oral pharmaceutical composition comprising carbamate compound and preparation method therefor |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID28529A (id) * | 1997-08-14 | 2001-05-31 | Hoffmann La Roche | Vinileter heterosiklik untuk gangguan neurologi |
| US6555585B2 (en) | 2000-07-21 | 2003-04-29 | Teva Pharmaceutical Industries, Ltd. | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
| DE60223506T2 (de) * | 2001-02-27 | 2008-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen |
| HUP0303243A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing and treating bipolar disorder |
| EP2623095A1 (en) | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| JP2010508354A (ja) * | 2006-10-31 | 2010-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 広汎性発達障害の処置 |
| AU2009348523B2 (en) | 2009-06-22 | 2015-02-26 | Sk Biopharmaceuticals Co., Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| EP3180329B1 (en) | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
-
2017
- 2017-12-14 CN CN201780077574.0A patent/CN110290788A/zh active Pending
- 2017-12-14 WO PCT/KR2017/014740 patent/WO2018111008A1/ko not_active Ceased
- 2017-12-14 KR KR1020197018408A patent/KR102635938B1/ko active Active
- 2017-12-14 EP EP17881161.8A patent/EP3556366B1/en active Active
- 2017-12-14 JP JP2019531623A patent/JP7208139B2/ja active Active
- 2017-12-14 US US16/468,782 patent/US11571410B2/en active Active
- 2017-12-14 ES ES17881161T patent/ES3054693T3/es active Active
- 2017-12-14 MX MX2019006940A patent/MX2019006940A/es unknown
- 2017-12-14 BR BR112019011930-2A patent/BR112019011930A2/pt not_active Application Discontinuation
- 2017-12-14 IL IL267195A patent/IL267195B2/en unknown
- 2017-12-14 AU AU2017374458A patent/AU2017374458B2/en active Active
- 2017-12-14 MY MYPI2019003348A patent/MY199104A/en unknown
-
2019
- 2019-06-11 ZA ZA2019/03747A patent/ZA201903747B/en unknown
- 2019-06-12 CL CL2019001618A patent/CL2019001618A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190314337A1 (en) | 2019-10-17 |
| IL267195B1 (en) | 2024-01-01 |
| AU2017374458A1 (en) | 2019-07-04 |
| AU2017374458B2 (en) | 2023-03-02 |
| BR112019011930A2 (pt) | 2019-10-29 |
| US11571410B2 (en) | 2023-02-07 |
| JP2020502106A (ja) | 2020-01-23 |
| WO2018111008A1 (ko) | 2018-06-21 |
| CA3046297A1 (en) | 2018-06-21 |
| EP3556366B1 (en) | 2025-10-22 |
| CL2019001618A1 (es) | 2019-08-23 |
| RU2019121913A (ru) | 2021-01-15 |
| EP3556366A4 (en) | 2020-06-17 |
| IL267195B2 (en) | 2024-05-01 |
| KR102635938B1 (ko) | 2024-02-13 |
| MX2019006940A (es) | 2019-09-06 |
| ZA201903747B (en) | 2021-01-27 |
| RU2019121913A3 (enExample) | 2021-04-21 |
| JP7208139B2 (ja) | 2023-01-18 |
| KR20190087572A (ko) | 2019-07-24 |
| CN110290788A (zh) | 2019-09-27 |
| EP3556366A1 (en) | 2019-10-23 |
| MY199104A (en) | 2023-10-13 |
| IL267195A (enExample) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7071287B2 (ja) | 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 | |
| EP3556366B1 (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder | |
| JP6986521B2 (ja) | 頭痛の予防的治療のためのカルバメート化合物の使用 | |
| JP6960415B2 (ja) | 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 | |
| ES2875058T3 (es) | Uso de compuestos de fenoxipropilamina para tratar la depresión | |
| JP7417595B2 (ja) | てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| ES2982316T3 (es) | Uso de un compuesto de carbamato para prevenir, aliviar o tratar las crisis de ausencia o la epilepsia que muestra crisis de ausencia | |
| ES2836685T3 (es) | Agente para aliviar la hiperactividad del detrusor con deterioro de la contractilidad | |
| RU2774970C2 (ru) | Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства | |
| ES2978226T3 (es) | Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático | |
| EP3556363B1 (en) | Use of carbamate compound for prevention, alleviation or treatment of pruritus | |
| KR20210062029A (ko) | 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도 | |
| ES2359910T3 (es) | Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso. | |
| HK40015213A (en) | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder | |
| JP4366533B2 (ja) | 睡眠障害の治療剤 | |
| ES2973111T3 (es) | Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio | |
| WO2007148950A1 (es) | Composición farmacéutica sinergística de ketorolaco y clonixinato de lisina | |
| HK40005640B (en) | Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia | |
| HK40005640A (en) | Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia | |
| BR112018073556B1 (pt) | Uso de um composto de carbamato | |
| TH98869A (th) | การบำบัดโดยใช้ยาร่วมกันกับ 5-htp |